February 14, 2024
3 min watch
Save
VIDEO: New drug delivery technologies decrease compliance issues in glaucoma
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, I. Paul Singh, MD, discusses how new opportunities in drug delivery can help limit reliance on patient compliance in glaucoma treatment.
Singh highlights Durysta (bimatoprost intracameral implant, Allergan) and iDose TR (travoprost intracameral implant, Glaukos) as two FDA-approved options for treating glaucoma.
“One of my biggest pearls, now having these opportunities, is to not ignore or minimize the impact of poor compliance,” he said.
Published by:
Sources/Disclosures
Collapse
Source:
Singh IP. Drug delivery pearls for 2024. Presented at: Hawaiian Eye 2024; Jan. 13-19, 2024; Wailea, Hawaii.
Disclosures:
Singh reports being a speaker and consultant for Allergan and Glaukos.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.